Dr. JeanMarie Guenot is an acclaimed manager known for her success in building and rebuilding companies. She has a vast experience running companies in different industries, and an equally vast portfolio of accomplishments. Here is an overview of her biggest accomplishments to date.
Education and Career Highlights
Amphivena’s bio page identifies that JeanMarie Guenot has extensive training in medicinal and physical chemistry. In particular, she has specialized in semi-empirical and quantum mechanical methods for molecular dynamics, NMR refinement, and drug design. She received her MBA from The Wharton School at the University of Pennsylvania and her PhD from the University of California.
Dr. JeanMarie Guenot’s career started at Atlas Venture where she was tasked with building life science companies and managing venture capital investments. However, her scientific career kicked off at Hoffmann La Roche where she was tasked with developing drugs for metabolic diseases, auto-immune diseases, inflammation, and oncology.
Over the years Dr. JeanMarie Guenot has worked in many industries in diverse positions, but mostly as a business administrator. Some of the sectors that she has worked in include business development, corporate and commercial development, venture capitalism, and pharmaceutical R&D. Today she is the president and CEO of Amphivena Therapeutics, Inc., which is seeking to overcome blood cancer and other chronic illnesses.
About Amphivena Therapeutics
Amphivena Therapeutics is a company that is championing the development of bi-functional antibody therapies for treating hematologic malignancies. A subsidiary of Affimed Therapeutics AG, the company was founded in 2012 and is headquartered in San Francisco, CA.
Since its establishment, Amphivena Therapeutics has been championing the development of therapeutic antibodies for the treatment of blood cancer, somethign Jeanmarie Guenot is passionate about. These therapeutic antibodies are designed to boost the patient’s natural immune system to produce antibodies that can bind to target molecules on tumor cells to destroy them. The company’s achievements in this quest include the development of tetravalent antibody-mimetic technology.
As a privately owned company, Amphivena Therapeutics is funded through venture capitalism. To date, the firm has raised $14 million in its Series A round of funding that was held in 2013. Investors who contributed to the first round of funding include its parent company Affimed Therapeutics AG, Aeris Capital, and MPM Capital. Currently, Jeanmarie has negotiated a partnership with Takeda, to work on new and innovative medical cures.